Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-04-19

FDA Approved: EDLUAR — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved Viatris Specialty LLC's supplemental application for EDLUAR (zolpidem tartrate), a brand product used to treat insomnia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EDLUAR (ZOLPIDEM TARTRATE)

Snippet

SUPPL AP for EDLUAR (ZOLPIDEM TARTRATE)